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ABSTRACT
Diarrhoea was estimated to account for 18% of the estimated 10.6 million deaths of children aged less 
than five years annually in 2003. Two—Africa and South-East Asia—of the six regions of the World Health 
Organization accounted for approximately 40% and 31% of these deaths respectively, or almost three-
quarters of the global annual deaths of children aged less than five years attributable to diarrhoea. Much of 
the effort to roll out low-osmolarity oral rehydration solution (ORS) and supplementation of zinc for the 
management of diarrhoea accordingly is being devoted to sub-Saharan Africa and to South and South-East 
Asia. A number of significant differences exist in diarrhoea-treatment behaviours and challenges of the 
public-health systems between Africa and Asia. The differences in rates of ORS use are the most common 
indicator of treatment of diarrhoea and vary dramatically by and within region and may significantly influ-
ence the roll-out strategy for zinc and low-osmolarity ORS. The prevalence of HIV/AIDS and the endemi-
city of malaria also differ greatly between regions; both the diseases consume the attention and financial 
commitment of public-health programmes in regions where rates are high. This paper examined how these 
differences could affect the context for the introduction of zinc and low-osmolarity ORS at various levels, 
including the process of policy dialogue with local decision-makers, questions to be addressed in formative 
research, implementation approaches, and strategies for behaviour-change communication and training 
of health workers.  
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INTRODUCTION
Over a quarter-century has passed since the intro-
duction of oral rehydration therapy (ORT) for di-
arrhoea in 1978 (1). ORT, including both prepack-
aged oral rehydration salts (ORS) and local recipes 
for home-fluids, remains the cornerstone of man-
agement of diarrhoea. ORT enables caregivers to 
manage dehydration in the home, decreases the 
need for intravenous fluids, and decreases rates of 
hospitalization and mortality. In 1980, diarrhoea 
was estimated to account annually for 4.6 million 
deaths of children aged less than five years (under-
five children) (2), while recent estimates for 2003 
attribute 18% or 1.9 million of 10.6 million annual 
deaths to diarrhoea, representing 3% of neonatal 
mortality and 17% of mortality in children aged 
1-59 month(s) (3). Two—Africa and South-East 
Asia—of the six regions of the World Health Orga-
nization (WHO) account for approximately 40% 
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and 31% deaths due to diarrhoea among children 
respectively, or almost three-quarters of the global 
annual deaths of children aged less than five years 
(under-five deaths) attributable to diarrhoea (3). 
This decrease in mortality is a great public-health 
success story, yet there has been limited or no de-
crease in rates of incidence of diarrhoea and mor-
bidity (4). Improved case management is an impor-
tant strategy to decrease the remaining 1.9 million 
childhood deaths attributable to diarrhoeal illness.   
In May 2004, the WHO and United Nations Chil-
dren’s Fund (UNICEF) issued new recommenda-
tions for the management of all episodes of child-
hood diarrhoea, including new low-osmolarity oral 
rehydration salts (ORS) and supplementation of 
zinc for 10-14 days (5). When properly deployed, 
these two advances in treatment will decrease mor-
bidity and enable further reductions in mortality 
due to diarrhoea. Low-osmolarity ORS continues to 
prevent and treat dehydration and also decreases 
stool volume by 25-30%, decreases the prevalence 
of vomiting by 30%, and decreases the need for un-
scheduled intravenous therapy by 30% (6-8). Sup-
plementation of zinc for 10-14 days decreases the 
duration and severity of the diarrhoea episode and 
decreases morbidity from diarrhoea and pneumo-
nia in the 2-3 months following treatment (9,10). 
Zinc is an effective treatment for diarrhoea and 
resembles a modern pharmaceutical (tablets or 
syrup); therefore, zinc has the potential to reduce 
inappropriate use of antimicrobials for childhood 
diarrhoea through a replacement effect. Results of a 
community-based trial in Bangladesh showed that, 
in areas where zinc was introduced into the man-
agement of diarrhoea, inappropriate use of antibio-
tics was significantly less than in control areas with-
out zinc treatment (11). Preliminary evidence from 
Mali and India also suggests that the introduction 
of zinc treatment may reduce the unnecessary use 
of antibiotics for diarrhoea (12,13). Child-health 
and nutrition programmes will not only need to 
develop strategies to promote low-osmolarity ORS 
and supplementation of zinc, they can also work 
to discourage antibiotic use for simple diarrhoea 
through replacement with zinc.  
There are now calls for a sustained effort to roll-out 
zinc and the new formulation of ORS and to ensure 
that it is in the hands of low-income and marginal-
ized populations who most need it (14,15). Such 
efforts should also promote continued feeding, ap-
propriate home-fluids, and breastfeeding.  
Rates of ORS use for the management of diar-
rhoea vary greatly throughout sub-Saharan Africa 
and South Asia, reflecting regional variations in 
promotion and acceptance of ORS. High rates of 
incidence of HIV and malaria represent an added 
burden to already struggling health systems. This 
paper focuses on how these three factors—(a) cur-
rent  childhood  diarrhoea-management  practices, 
(b) prevalence of HIV, and (c) endemicity of ma-
laria—affect  the  context  of  introduction  of  low-
osmolarity  ORS  and  supplementation  of  zinc  at 
various levels: national policy, health programmes, 
health facilities, and households. We demonstrate 
that current rates of ORS use, HIV/AIDS, and ma-
laria might affect the process of policy dialogue 
with local decision-makers, dictate questions to be 
addressed through formative research, and influ-
ence strategies for behaviour-change communica-
tion and training of health workers. 
SETTINGS FOR INTRODUCTION  
OF ZINC AND NEW ORS
For the purpose of this paper, countries in these 
two regions have been classified by rates of ORS use 
and rates of prevalence of HIV/AIDS and malaria 
(Table 1). These classifications are not intended to 
be comprehensive, but rather to illustrate the range 
of variation among countries and states in these 
two regions. For this reason, many, if not most, 
countries do not fit neatly into any one of the five 
settings described in Table 1.  
a.  Countries in this first category are primarily 
francophone, in the Sahel region of West Africa, 
and have among the highest levels of under-five 
mortality  in  the  entire  world  (150-200/1,000 
livebirths), low rates of ORS use (10-20%), high 
levels of malaria-related morbidity and morta-
lity, relatively low but increasing prevalence of 
HIV, and relatively poor access to government 
health facilities. The 2003 Lancet child-survival 
series describes five profiles or patterns of un-
der-five mortality in countries with high rates 
or contributing large numbers of under-five 
deaths (16).  These countries were classified in 
Profile 2 in this typology of countries by under-
five mortality pattern (16).
b.  This setting includes countries of southern Afri-
ca characterized by high ORS use, lower but still 
considerable under-five mortality (60-70/1,000 
livebirths), overall high prevalence of HIV (over 
20%), and highly seasonal and focal transmis-
sion of malaria, resulting in a relatively low bur-
den of malaria-related disease. These countries 
were assigned to Profile 5 in the 2003 Lancet 
series (16).
c.  Countries in this setting include nations of 
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Table 1. Public-health settings* for the roll-out of low-osmolarity ORS and zinc supplementation 
for management of diarrhoea in sub-Saharan Africa and South Asia
Characteristics Setting 1 Setting 2 Setting 3 Setting 4 Setting 5
Sahel Region
Low ORS use, 
high burden 
of childhood 
malaria 
Southern 
Africa
High ORS 
use, high 
burden of 
HIV 
Eastern and 
southern 
Africa
Medium to 
high ORS 
use, high 
burden of 
HIV, and 
childhood 
malaria 
South Asia 
Medium-
high under-
five mortal-
ity, low ORS 
use
South Asia
High ORS 
use
Examples Mali, Chad, 
Niger, Burki-
na Faso
South Africa, 
Namibia, 
Botswana
Uganda, Tan-
zania, Zam-
bia, Malawi
Bihar State 
and Uttar 
Pradesh 
States, India
Bangladesh
<5 mortality  
   rate/1,000 
   livebirths 175-200 60-80 110-180 100-125 60-80
Child health 
   profile, Lancet 
   series 2003 
Profile 2 Profile 5 Profile 4 Profile 1 Profile 1
HIV prevalence 1-6% 20-30% 4-20% <1% <1%
Malaria 
   transmission
Endemic in 
areas with 
adequate 
rainfall
Limited areas 
of transmis-
sion
Endemic in 
areas with 
adequate 
rainfall
Limited areas 
of transmis-
sion
Limited areas 
of transmis-
sion
Rates of ORS use 10-20% 50-70% 30-60% 10-20% >60%
Availability of 
   ORS sachets
Often only 
available 
in health 
facilities and 
pharmacies
Widely avail-
able through 
public and 
private sec-
tors
Widely avail-
able through 
public sector, 
less in pri-
vate sector
Widely avail-
able through 
public and 
private sec-
tors 
Widely avail-
able through 
public and 
private sec-
tors
Production of 
   ORS sachets
Often im-
ported, some 
local produc-
tion
Multiple pro-
ducers, many 
flavours and 
brands 
Some local 
production, 
sometimes 
imported
Multiple pro-
ducers, many 
flavours and 
brands
Multiple pro-
ducers, many 
flavours and 
brands
Marketing of 
ORS sachets
Limited 
private sector 
marketing, 
limited MoH 
promotion
Some private 
sector mar-
keting, some 
MoH promo-
tion 
Some private 
sector mar-
keting, some 
MoH promo-
tion
Visible 
marketing 
of different 
brands, some 
MoH promo-
tion
Visible 
marketing 
of different 
brands, some 
MoH promo-
tion
Population 
density
Generally 
low
Low density 
in rural, large 
urban popu-
lation 
Low in rural 
areas, grow-
ing urban 
population
High High
*Settings are not comprehensive; many countries do not fit one of these settings
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of the 2003 Lancet series (16), with medium-
to-high under-five mortality (110-180/1,000 
livebirths), medium-to-high ORS use (30-60%), 
overall  medium-to-high  prevalence  of  HIV 
(4-20%), and extensive malaria-related mortal-
ity and morbidity.
d.  This category includes countries of South Asia 
corresponding to Profile 1 in the Lancet series 
(16), with medium high under-five mortality 
(100-125/1,000 livebirths), low ORS use (10-
20%), and a relatively small burden of disease 
attributable to HIV/AIDS and malaria compared 
to the countries mentioned above.  
e.  The final setting is represented by parts of South 
Asia with lower but still considerable under-five 
mortality (60-80/1,000 livebirths), high ORS 
use (over 60%), and a relatively small burden 
of disease attributable to HIV/AIDS and malaria 
(14,17).
CURRENT RATES OF ORS USE 
ORS and ORT have been recommended for the 
treatment and prevention of dehydration since the 
late 1970s (1). Since the early promotional cam-
paigns, some countries have placed more emphasis 
more on recommended home-fluids, while others 
have vigorously promoted and made available ORS 
sachets through the public or private sectors, or 
both (1); the definitions of appropriate home-fluids 
also vary greatly across countries. For these reasons, 
comparison of rates of ORS use between countries, 
states, or even regions does not adequately describe 
whether management of diarrhoea in the home is 
better in one place versus another. Nevertheless, 
since it is expected that low-osmolarity ORS and 
zinc will be distributed through the same mecha-
nisms as the currently-available ORS sachets, rates 
of ORS use provide key information for the plan-
ning of strategies for the introduction of new diar-
rhoea-treatment guidelines.  
Table 2 shows rates of ORS use based on the de-
mographic and health surveys (DHS). There is a 
tremendous variation within region in both South 
and South-East Asia. Low levels of ORS use are ob-
served throughout West Africa, except Ghana and 
Guinea. Reasons for low levels of ORS use in West 
Africa  include  greater  promotion  of  home-avail-
able fluids than ORS in some countries, user-fees, 
and charges for products, such as ORS sachets in 
health facilities or community pharmacies operat-
ing under the principles of the Bamako Initiative 
(18), and poor geographic access to health facilities 
and pharmacies (19). High levels of ORS use were 
observed across southern Africa (Namibia, South 
Africa, and Zambia) and to some extent continu-
ing up into east Africa (Tanzania and Uganda).
In South and South-East Asia, the lowest levels of 
ORS-use were observed in Cambodia and in the 
Hindi-speaking States of the Gangetic Plain (Uttar 
Pradesh and Bihar), while the highest levels were 
observed in Bangladesh, Viet Nam, The Philip-
pines, and the smaller Indian States, such as Kerala, 
Manipur, and Goa. Factors contributing to lower 
levels of ORS-use in parts of South Asia include low 
levels of knowledge and awareness of ORS among 
some groups (20) and poor access to health services 
because of poverty and social marginalization of 
certain caste and ethnic groups (21).
Where rates of ORS use are high, ORS sachets are 
generally widely available, affordable, or free of 
charge (22) and their value for prevention and treat-
ment of dehydration widely recognized (23,24). In 
these settings, formative research might examine 
current sources of ORS and consumer preferences 
for ORS and other treatments of diarrhoea and 
use this information to take advantage of existing 
distribution channels for the introduction of zinc 
supplementation. Where ORS is available free of 
charge, it is more likely that zinc may be available 
free of charge which will accelerate rates of uptake, 
especially among the very poor. In addition, loca-
tions with already high rates of ORS use may be in 
the best position to benefit from expanded private-
sector social marketing campaigns for zinc and new 
ORS. In contrast, low rates of ORS use are associated 
with low awareness and knowledge of ORS among 
caregivers (25), poor availability at the community 
level (26), perceived high cost of ORS, or the mis-
conception among both prescribers (27,28) and 
consumers (29) that antibiotics, antidiarrhoeals, or 
other treatments are effective medications for diar-
rhoea. These different factors, and how approaches 
to promote zinc and the new ORS can be adapted 
to these difficulties, should be examined through 
formative research.
The availability of and access to ORS sachets vary 
greatly between regions and can have a signifi-
cant impact on use-rates. In many Asian countries, 
ORS  sachets  are  available  through  various  chan-
nels, such as health facilities, general stores, and 
medicine shops (22), and population densities are 
higher, all of which favours better geographic ac-
cess to the product. The private Asian market has 
led to the widespread availability of ORS sachets 
and a competing private sector that does not de-Winch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
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pend on donor funds for promotion campaigns.   
The competition has led to a wide array of prod-
ucts boasting various flavours and brand names, al-
though formulations are not always in accordance 
with the recommendations of WHO (30). Where 
ORS  is  largely  produced  within  country,  govern-
ments may be able to control how fast changes to 
the new formulation of ORS take place through 
policies requiring companies to produce the new 
formulation of ORS. It will be critical that govern-
ments take steps to ensure that low-osmolarity ORS 
sachets are supplied to both public and private sec-
tors. Additional education to teach healthcare pro-
viders and consumers about the added value of the 
new formulation should accompany changes in 
policy and regulation.  
Across southern Africa, ORS sachets tend to be 
readily available through both public and private 
channels, whereas in West Africa, ORS sachets are 
frequently available only at health facilities and 
pharmacies. These are few in number, making it 
difficult for people to access ORS, particularly in 
the rainy season. With the introduction of zinc 
and new ORS, strong advocacy should be carried 
out for policies which promote the increased ac-
cess and availability of these products through 
private and community distribution channels. Af-
rican countries also tend to not have as many local 
manufacturers of ORS as Asian countries do, there-
fore may only have one public-sector supplier and 
no private-sector ORS market. The adoption of the 
new formulation of ORS may be dependent upon 
the rate at which exporters of ORS adapt to the new 
formulation. In some cases, suppliers of ORS are 
producing both original and low-osmolarity ORS, 
but are only providing the new formulation when 
requested, thus leaving the choice of which formu-
lation up to the procuring body.
Table 2. Percentage of children with diarrhoea in the last two weeks who received ORS in sub-
Saharan Africa and South and South-East Asia as measured by DHS surveys, 1998-2006
ORS-use 
rates (%)
Sub-Saharan Africa 
country and year of DHS survey
(%: Country and year of survey)
South and South-East Asia 
country and year of DHS survey
(%: Country and year of survey)
<20 12.4: Madagascar 2003/2004
13.1: Ethiopia 2000 
13.6: Rwanda 2000 
14.0: Mali 2006
15.1: Chad 2004
16.8: Cameroon 2004 
17.1: Togo 1998
17.6: Niger 2006
18.2: Nigeria 2003 
18.9: Burkina Faso 2003 
17.8: Cambodia 2000
20-29 20.4: Senegal 1999
22.6: Mauritania 2000/2001 
23.6: Côte d’Ivoire 1998/1999
24.8: Gabon 2000 
29.2: Kenya 2003
28.8: India 1998-1999
30-39 33.5: Uganda 2000/2001 
34.5: Guinea 1999
38.6: Ghana 2003
32.2: Nepal 2001
38.8: Pakistan 1990/1991
35.5: Indonesia 2002/2003
40-49 44.7: Eritrea 2002 
47.9: Malawi 2000 
48.5: Mozambique 2003
40.0: Viet Nam 2002
42.2: The Philippines 2003
50-59 51.2: South Africa 1998
53.2: Zambia 2001/2002  
53.9: Tanzania 2004-2005
60-69 61.1: Namibia 2000 67.7: Bangladesh 2004
DHS=Demographic and health survey; ORS=Oral rehydration saltsWinch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
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POTENTIAL EFFECTS OF  
MALARIA AND HIV/AIDS
The epidemiology of malaria and HIV/AIDS differs 
greatly across the five settings, with rates of child-
hood malaria highest in Setting 1 and 3 and HIV/
AIDS taking the greatest toll in Setting 2 and 3. The 
presence of these diseases can affect the receptive-
ness of a given setting to introduction of zinc and 
low-osmolarity ORS and the feasibility of attaining 
an adequate coverage with these interventions (Ta-
ble 3). The following paragraphs review the poten-
tial effects across five categories of considerations, 
as summarized in Table 3: (a) Policy, (b) Commodi-
ties and procurement, (c) Personnel, (d) Quality of 
care, and (e) Home-care.
Policy 
Prior to the introduction of zinc and low-osmolar-
ity ORS for diarrhoea, policy-makers and decision-
makers in the Ministry of Health will review the 
recommendations and evidence supporting their 
introduction  and  discuss  options  for  implemen-
tation. High rates of HIV/AIDS and malaria may 
greatly  complicate  this  process.  Policy-makers 
are currently engaged in discussions about recom-
mendations for the treatment of HIV and malaria, 
financing strategies for these expensive treatments, 
and how to mitigate the impact of HIV/AIDS on 
communities, including provision of care for or-
phans  and  other  vulnerable  children.  This  may 
leave decision-makers with little time to deliberate 
on new diarrhoea-management policies. Further-
more, in the presence of endemic malaria or high 
prevalence of HIV, diarrhoeal disease may be regard-
ed as a relatively unimportant public-health prob-
lem. Finally, there may be concerns that treatment 
with zinc could adversely affect the clinical course 
of AIDS, although data have shown that supple-
mentation of zinc is safe and effective when given 
for diarrhoea in HIV-1-infected children (31).
Commodities and procurement 
Adaptation  of  new  diarrhoea-management 
guidelines will likely be most successful where low-
osmolarity ORS and zinc will be widely available 
either free of charge or at a nominal cost. Past expe-
rience has demonstrated that where fees for treat-
ments  are  instituted,  coverage  can  be  negatively 
impacted, especially among poorer families (32). In 
Setting 1, 2, and 3, issues relating to procurement 
or local production, cost and distribution of AIDS 
antiretroviral therapy, combination treatment of 
malaria, mosquito nets, insecticides, and other 
products may take priority over addressing issues 
of supply for low-osmolarity ORS and supplemen-
tation of zinc. Finally, pharmaceutical companies 
may see a greater potential for profit in production 
and marketing of antimalarials, antiretrovirals, an-
tibiotics, or inappropriate antidiarrhoeals than in 
production of zinc. Zinc supplements do not re-
quire advanced technology, thus production at the 
local level is possible. However, companies may be 
hesitant to start product development prior to hav-
ing a commitment from the government that there 
will be a market for the supplements. Because the 
new formulation of ORS requires only a change to 
the formulation, production of the low-osmolarity 
ORS requires only a decision on the part of the 
manufacturer to make the switch.
Personnel 
The availability of trained personnel can be impact-
ed by high rates of HIV/AIDS and malaria, either 
directly by increasing rates of morbidity and mor-
tality among qualified health workers, or indirectly 
through effects on health systems. Many interven-
tions to reduce the burden of HIV/AIDS and ma-
laria are being implemented through categorical 
(disease-specific) control programmes. Categorical 
programmes can weaken health systems by hir-
ing already scarce personnel away from existing 
services into new categorical programmes, or offer-
ing specific courses, meetings, and other activities 
that take away from general patient care (33), 
although there is some evidence that categorical 
programmes may improve the management of 
health systems and community relations (34). In 
these areas, the introduction of zinc and new ORS 
should  focus  on  strengthening  existing  primary-
care  and  community-care  infrastructure  through 
training of personnel and reinforcing the inte-
gration of management of diarrhoea within the 
overall health system.  
Quality of care 
Complex clinical presentations of diarrhoea among 
HIV-positive young children require greater skills 
to  manage  appropriately.  Acute  diarrhoea  occurs 
more often in HIV-infected children, and episodes 
tend to be more severe and persistent (35,36) and 
are much more likely to lead to death (35).  Fur-
thermore, HIV-positive children are more likely to 
have concurrent symptoms of dehydration and 
fever (37) or co-morbidities, such as pneumonia 
(36), leading to a greater proportion of episodes 
requiring care at higher-level facilities, rather than Winch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
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in homes or in the community. Therefore, in re-
gions with significant prevalence of childhood HIV, 
training modules for health workers, job aids, and 
reporting forms relating to management of diar-
rhoea must be adapted to account for more severe 
presentations of diarrhoeal illness among HIV-posi-
tive children.  
Although there is little scientific evidence support-
ing biological interaction of malaria and diarrhoea 
(38-40), the coincidental occurrence of malaria and 
diarrhoea concurrently is well-documented, and 
children often present to healthcare providers with 
symptoms of both diarrhoea and fever or history of 
fever (40,42,43). In highly malaria-endemic coun-
tries, a typical recommendation is for all children 
aged less than five years presenting with fever or 
history of fever to be presumptively treated with 
an antimalarial (44). Therefore, in these areas, chil-
dren presenting with fever and diarrhoea will need 
to receive zinc, ORS, and antimalarial treatment. 
Efforts will be needed to promote understanding of 
these new treatment guidelines in both formal and 
informal sectors. 
Home-care  
Household structure: Thus far, pilot interventions 
introducing supplementation of zinc and low-
osmolarity ORS have relied upon community ed-
ucation on management of diarrhoea to increase 
treatment-seeking from public and private sources 
and, hence, improve management of diarrhoea. 
In countries where prevalence rates of HIV are 
high, severe illness and death among young adults 
have led to an enormous increase in the number 
of households headed by parents incapacitated by 
illness, elderly caregivers, or older children (45,46). 
Severe illness or absence of an adult caregiver can 
impact both home management and care-seeking 
behaviour for episodes of childhood diarrhoea. In 
Zaire, among HIV-negative children, those whose 
mothers were HIV-positive were two times more 
likely to develop persistent diarrhoea than chil-
dren of uninfected mothers; HIV-negative chil-
dren whose mothers died of HIV infection were 10 
times more likely to develop persistent diarrhoea 
(35). Limited evidence from Uganda suggests that 
child-headed households have less knowledge 
about mild and severe malaria and are significantly 
less likely to seek care from health facilities and are 
more likely to use herbal remedies to treat malaria 
than adult-headed households (47). In such a set-
ting, community-level infrastructure established to 
facilitate access to treatment of AIDS and mitigate 
the effects of AIDS may also be an effective platform 
for the promotion of improved management of di-
arrhoea and a way to reach vulnerable children.
Perceptions  of  care-givers  about  childhood  diarrhoea: 
Diarrhoea is often considered not as severe or life-
threatening  as  malaria  or  HIV/AIDS,  thus  nega-
tively  affecting  care-seeking  and  treatment 
patterns. Results of our work in Mali showed that 
parents  commonly  perceived  that  diarrhoea  is  a 
symptom caused by malaria (12). This misconcep-
tion results in many children with diarrhoea and 
fever only receiving treatment of malaria with no 
recommendation for ORS or home-fluids (12). 
Therefore, during the introduction of zinc in these 
areas, communication campaigns should also focus 
on the potential severity of diarrhoea as an illness 
and cause of child death, not merely a symptom of 
other illnesses.  
When any new treatment is introduced, there 
is the risk that it may displace treatments being 
used previously. This is both an opportunity and 
a challenge. In the case of inappropriate antibio- 
tics and antidiarrhoeals, zinc may successfully 
displace these treatments. However, in countries 
where malaria is endemic, it is important to en-
sure that zinc is not perceived as a replacement for 
antimalarials. Children who present with both fe-
ver and diarrhoea should receive an antimalarial 
drug, zinc, and ORS/ORT. In a pilot introduction 
of zinc for the management of diarrhoea in Mali, it 
was observed that many children with both fever 
and diarrhoea received zinc and ORS but did not 
receive an antimalarial; families and community 
health workers viewed zinc as a medicine sufficient 
to treat both the illnesses (48). Remedial immediate 
actions were taken to improve and integrate com-
munity and home management of diarrhoea and 
malaria. New first-line artemisinin-based combina-
tion therapies are expensive, and their cost may 
prove prohibitive to families (49,50); families may 
perceive the new zinc treatment as a lower-cost al-
ternative to artemisinin combination therapy for 
children with diarrhoea and fever. Training and 
communications materials for the introduction of 
zinc and new ORS must be integrated with child-
hood malaria-management strategies to ensure that 
both the diseases are adequately treated. Addition-
ally,  communication  strategies  to  introduce  new 
treatments for malaria and diarrhoea must work 
to create a distinct identity for zinc tablets and be 
coordinated in their choice of product names, lo-Winch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
JHPN 8
gos, and explanations of properties of medicines. 
Monitoring the treatment patterns for both diar-
rhoea and malaria will be important early on to en-
sure that zinc is replacing unnecessary antibiotics, 
but not replacing antimalarials.    
CONCLUSIONS
In this paper, we have argued for the importance 
of considering rates of ORS use, endemicity of ma-
laria, and rates of prevalence of HIV when plan-
ning for the introduction of zinc supplementation 
and low-osmolarity ORS for childhood diarrhoea. 
Research and evaluation of zinc supplementation 
thus far have focused on clinical outcomes with 
regard to HIV/AIDS and malaria, i.e. efficacy and 
safety measures. These are critical questions to ad-
dress, but the vast impact that HIV/AIDS and ma-
laria can have on health systems and how this will 
impact the process of revitalizing diarrhoea-control 
efforts also merit consideration and further study. 
In this paper, we have demonstrated that, when 
planning for the introduction of zinc and low-os-
molarity ORS in a country where HIV/AIDS and/or 
malaria are important public-health problems, it is 
absolutely crucial to examine the direct and indi-
rect effects the presence of these diseases may be 
having on (a) the policy environment and policy-
makers, (b) the supply chain for medications and 
other health-related commodities, (c) the avail-
ability of human resources in the health sector, (d) 
the quality of case management by health workers, 
and (e) home management of diarrhoea by parents 
(Table 3).
Considering only rates of ORS use, endemicity of 
malaria, and rates of prevalence of HIV, the most 
favourable context for the accelerated introduction 
of zinc and low-osmolarity ORS will be where cur-
rent rates of ORS use are high, and the burden of 
disease attributable to HIV/AIDS and malaria is low. 
This situation is represented by Setting 5 in Table 
1. The overall environment for the introduction of 
zinc and low-osmolarity ORS is favourable due to 
the high awareness of the impact of diarrhoeal dis-
ease in the public-health community, and good lo-
cal capacity for production and promotion of zinc 
and ORS.  
Setting 1 and 4, where rates of ORS use are the 
lowest, may present the greatest challenges to in-
troduction of these new treatments. If the lowest 
rates are due to ORS being unavailable, efforts may 
be needed to both promote local manufacturing of 
zinc and ORS and ensure that these products are 
available through multiple public and private dis-
tribution channels. Although the burden of disease 
attributable to HIV is currently lower compared to 
other countries, these regions have difficulties in 
achieving high coverage with other critical public-
health interventions. Thus, achieving coverage of 
zinc  and  low-osmolarity  ORS  may  require  addi-
tional technical assistance to overcome challenges. 
The francophone countries in Setting 1 are charac-
terized by high levels of under-five mortality, weak 
health services, poor transport, and limited ability 
of governments to implement policies and provide 
services  (51).  Under  these  conditions,  the  intro-
duction of new diarrhoea-management guidelines 
may have the most success if coordinated with 
other child-health initiatives, such as UNICEF’s Ac-
celerated Child Survival and Development (ACSD) 
in West Africa and other large-scale programmes. 
In Setting 4, communication and transport infra-
structures are far better than in Setting 1, but mor-
tality levels remain high because it is difficult to 
ensure that health and nutrition interventions are 
delivered to the poorest wealth quintiles and mar-
ginalized groups. The Government of India and 
State governments are actively implementing pro-
grammes to overcome the constraints to decreas-
ing under-five mortality, especially in challenging 
regions. Again, efforts need to be made to integrate 
the  introduction  of  new  diarrhoea-management 
guidelines with these initiatives.
In Setting 2 and 3, considerable progress has been 
made in strengthening health systems, and this is 
reflected in the high rates of ORS use and lower lev-
els of under-five mortality compared to many other 
parts of Africa. HIV/AIDS threatens to reverse many 
of these gains and is a constant concern in the 
minds of policy-makers, health workers, and com-
munities. In Setting 3, the challenge of HIV/AIDS is 
overlaid on the persistent high malaria-related bur-
den of disease. In Setting 2 and 3, strong advocacy 
before policy-makers for investments to improve 
case management of diarrhoea is required. At the 
household  and  community  levels,  promotion  of 
appropriate management of diarrhoea should be 
complemented by adequate care and support for 
orphans  and  other  vulnerable  children.  As  with 
Setting 1 and 4, we need to seek new ways of inte-
grating ongoing efforts of new diarrhoea-manage-
ment guidelines directed at HIV/AIDS and malaria 
through better training and supervision of health 
workers and other measures to improve quality of 
care.
It is widely appreciated that national strategies to 
introduce zinc for the management of diarrhoea Winch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
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and new low-osmolarity formulation of ORS must 
be adapted through formative research to take into 
account local understandings of diarrhoea and 
home-management practices. What is less well-ap-
preciated is the enormous impact the other public-
health problems, such as malaria and HIV/AIDS, 
can have on the environment for the introduction 
of these new treatments, as summarized in Table 3. 
Consideration of this situation necessarily widens 
the scope of formative and operations research and 
calls for us to carefully tailor strategies for advocacy 
of these new treatments and coordination of this 
introduction with other health initiatives.
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Table 3. Effects of malaria and HIV/AIDS on introduction of zinc and low-osmolarity ORS for 
diarrhoea
Policy
   Effects on  
      policy-makers 
      and the process 
      of policy dialogue
  Competition for attention of policy-makers where HIV and malaria 
demand a large portion of their time  
  Low priority assigned to diarrhoeal diseases compared to HIV and 
malaria
  Concern that zinc treatment might affect clinical course of AIDS
Commodities  
   Supply of zinc and 
      new ORS
  Production, cost, and distribution of AIDS antiretroviral therapy, 
tools for HIV prevention and control, malaria combination treat-
ment, and malaria-prevention tools may take priority over address-
ing supply of low-osmolarity ORS and treatment with zinc
  Competition with HIV and malaria drugs, tools, and vaccines for 
budget allotments 
  Pharmaceutical companies may see greater potential for profit in 
production of antimalarial and antiretroviral treatments
Personnel  
   Availability of 
      human resources 
      in the health 
      sector
  Competition for scarce human resources from other disease-control 
programmes
  Competition for time of health workers: training courses, meetings, 
supervision
  Morbidity and mortality in health workers due to AIDS or malaria
Quality of care
   Quality of case 
   management by 
   health workers
  Clinical presentation of diarrhoea is more complex in children with 
HIV
  Confusion/overload in health workers relating to new guidelines for 
case management especially if they are not integrated with existing 
guidelines 
  Emphasis by health workers often placed on management of fever/
malaria than management of other illnesses
Home-care
   Home management 
     of diarrhoea by 
     parents or other 
     caretakers of 
     young children
  Sickness or death of parents from AIDS or malaria results in house-
holds headed by elderly caregivers or children, difficult for these 
caregivers to absorb new guidelines for the management of diarrhoea
  Diarrhoea might be perceived as symptom of malaria (12) rather 
than a separate condition meriting specific treatment
  Results of formative research in southern Mali shows that health 
workers are likely to over-diagnose malaria giving antimalarials to a 
wider range of childhood illnesses, including diarrhoea
  Results of a pilot study in Mali showed that multiple treatments were 
beyond  the financial means of families and difficult to administer 
correctly
ORS=Oral rehydration saltsWinch PJ et al. Zinc treatment and low-osmolarity ORS for childhood diarrhoea
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